De Las Casas Luis E, Hicks David G
University of Rochester Medical Center, Rochester, NY, USA.
Am J Clin Pathol. 2021 May 18;155(6):781-792. doi: 10.1093/ajcp/aqaa212.
Tumor biomarker analyses accompanying immuno-oncology therapies are coupled with a tumor tissue journey aiming to guide tissue procurement and allow for accurate diagnosis and delivery of test results. The engagement of pathologists in the tumor tissue journey is essential because they are able to link the preanalytic requirements of this process with pathologic evaluation and clinical information, ultimately influencing treatment decisions for patients with cancer. The aim of this review is to provide suggestions on how cancer diagnosis and the delivery of molecular test results may be optimized, based on the needs and available resources of institutions, by placing the tumor tissue journey under the leadership of pathologists.
Literature searches on PubMed and personal experience provided the necessary material to satisfy the objectives of this review.
Pathologists are usually involved across many steps of the tumor tissue journey and have the requisite knowledge to ensure its efficiency.
The expansion of oncology diagnostic testing emphasizes the need for pathologists to acquire a leadership role in the multidisciplinary effort to optimize the accuracy, completeness, and delivery of diagnoses guiding personalized treatments.
免疫肿瘤治疗过程中的肿瘤生物标志物分析与肿瘤组织流程相关联，旨在指导组织获取，并实现准确诊断和检测结果的传达。病理学家参与肿瘤组织流程至关重要，因为他们能够将该过程的分析前要求与病理评估及临床信息相联系，最终影响癌症患者的治疗决策。本综述的目的是基于机构的需求和可用资源，通过让病理学家领导肿瘤组织流程，就如何优化癌症诊断和分子检测结果的传达提供建议。
通过在PubMed上进行文献检索并结合个人经验，提供了满足本综述目标所需的材料。
病理学家通常参与肿瘤组织流程的多个步骤，并且具备确保其高效运行的必要知识。
肿瘤学诊断检测的扩展强调了病理学家在多学科工作中发挥领导作用的必要性，以优化指导个性化治疗的诊断的准确性、完整性和传达。
